CV DEATH HAS A NEW OPPONENT
CV DEATH HAS A NEW OPPONENT

Empagliflozin's Proven Efficacy and safety in HF patients with or without T2D

Document ID: PC-PH-104581

27/03/2023

Author: Boehringer Ingelheim

Related content

 
PC-PH-104581
Production date: March 2023